IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of ...

Interim phase 3 trial data show that atacicept reduces proteinuria over 36 weeks in patients with IgA nephropathy. Patients with IgA nephropathy treated with atacicept experience substantial reduction ...

HOUSTON — Atacicept, an investigational dual B-cell activating factor and a proliferation-inducing ligand (BAFF/APRIL) inhibitor, showed substantial reductions of proteinuria and benefits in other ...

The cytokine A proliferation-inducing ligand (APRIL) is considered a key driver of the pathogenesis of IgA nephropathy. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and ...

Clinicians face exciting new options in immunoglobulin A (IgA) nephropathy, with recent accelerated FDA approvals and positive data presented on agents targeting B-cell activating factor (BAFF) and a ...

At the American Society of Nephrology Kidney Week meeting, interim results from the phase III ORIGIN 3 trial showed that investigational atacicept led to a 46% reduction in proteinuria at 36 weeks in ...

Vertex said a drug it secured as part of a $4.9 billion acquisition successfully reduced by half a key marker of a kidney ...

The FDA granted accelerated approval to sibeprenlimab injection (Voyxact) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy at risk for disease progression, ...

Povetacicept significantly reduced proteinuria in patients with IgA nephropathy in the RAINIER trial, supporting an upcoming FDA submission.

Povetacicept substantially reduced proteinuria with stable eGFR over 48 weeks in patients with IgAN or pMN, according to interim data from the phase 1/2 RUBY-3 trial. Povetacicept safely reduces ...

ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc. (TVTX), support the recent publication of the updated clinical practice guidelines for ...